We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarker Identified for Novel Asthma Treatment

By LabMedica International staff writers
Posted on 17 Sep 2018
Asthma is a widespread chronic airway disease characterized by airway obstruction, inflammation, and hyperresponsiveness. More...
Symptoms such as bronchoconstriction and cough range from mild intermittent to severe persistent.

In eosinophilic asthma, the most common form of asthma, eosinophils in the airway alter nerve function and exacerbate the disease. However, whether eosinophils also affect airway nerve structure is unclear. In type 2-high asthma, interleukin-5 (IL-5) promotes eosinophil maturation, recruitment, and survival.

An international team of scientists working with the Oregon Health and Science University (Portland, OR, USA) evaluated airway sensory innervation and eosinophilia in humans with and without asthma and to characterize the physiologic consequences of eosinophil and airway nerve interactions using transgenic mice. Patients over the age of 17 were recruited and medication use, pulmonary function testing, blood eosinophil counts, serum immunoglobulin E (IgE) levels, and smoking history were obtained.

Human bronchial biopsies (three to five per subject) were taken from the bifurcation of the right middle lobe and immediately fixed in formalin overnight. Tissues were immunostained at 4 °C on a shaker. Airway nerves were labeled with rabbit polyclonal antibody against pan-neuronal marker PGP9.5 (protein gene product 9.5), and other immunostaining was performed and images were acquired using a Zeiss LSM 780 confocal microscope.

The scientists reported that subjects with a type 2-high asthma phenotype, defined as blood eosinophils greater than 300 cells/μL, had longer airway nerves and increased nerve branch points compared to control airways. In contrast, nerves in type 2-low asthmatics with blood eosinophils less than 300 cells/μL were not significantly different from healthy subjects. The mean blood eosinophils counts were 182 ± 93 μL in the 19 controls; 277 ± 289/μL in the 13 intermittent asthma patients; and 301 ± 225/μL in the persistent asthma sufferers. Moderate persistent asthmatics had increased eosinophil peroxidase both above and below the epithelial basement membrane compared to mild intermittent asthmatics and control subjects.

The authors concluded that their data indicated that airway nerves contribute to asthma pathology. They have shown that moderate persistent asthmatics have increased airway sensory innervation that is especially marked in asthmatics with accompanying eosinophilia. Richard W. Costello, MB, MD, FRCPI, a professor and a senior author of the study, said, “We identified that inflammatory cells, in particular, eosinophils, promote airway nerve growth in patients with asthma. These observations provide a unique insight into a fundamental mechanism of how the inflammation caused by asthma causes people to experience the symptoms of asthma such as coughing and breathlessness. This means that we now know which markers to look for in a patient with severe asthma. A patient with markers which show they have this particular form of asthma is likely to respond well to these new treatments.” The study was published on September 5, 2018, in the journal Science Translational Medicine.

Related Links:
Oregon Health and Science University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.